94670-70-9

Basic information

• Product Name: Carbamic acid, [3-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester, (S)-
• CAS NO: 94670-70-9
• Molecular Formula: C15H23NO3
• Molecular Weight: 265.353
• Mol File: 94670-70-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [3-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [3-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester, (S)-(94670-70-9)
• EPA Substance Registry System: Carbamic acid, [3-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester, (S)-(94670-70-9)

Safety Data

• Hazardous Substances Data: 94670-70-9(Hazardous Substances Data)

Upstream product

• 60398-41-6 (3S)-tert-butyl 1-benzyl-3-diazo-2-oxopropylcarbamate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 51871-62-6 (S)-3-tert-butoxycarbonylamino-4-phenylbutanoic acid 
• 103127-52-2 ((S)-1-benzylallyl)carbamic acid tert-butyl ester 
• 60398-42-7 methyl (3S)-3-{[(tert-butoxy)carbonyl]amino}-4-phenylbutanoate 

Downstream Products

• 904324-64-7 [1-benzyl-3-(5-bromo-pyridin-3-yloxy)-propyl]-carbamic acid tert-butyl ester 
• 1031684-82-8 [(1S)-3-bromo-1-(phenylmethyl)propyl]carbamic acid tert-butyl ester 
• 1169870-36-3 C₃₆H₄₅N₇O₅S₂ 
• 1169870-34-1 C₃₆H₄₆N₆O₄S₂ 
• 1169870-28-3 C₃₆H₅₃N₇O₅S₂ 
• 1169870-26-1 C₂₅H₃₅N₃O₅S 
• 1169870-25-0 C₂₇H₃₇N₃O₆S 
• 1169870-18-1 C₃₉H₅₁N₇O₅S₂ 

Relevant articles and documents

SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS

The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is hydrogen or fluoro; L1 is -CH2-, -NR'-, -0-, -S-, CF2- or CH=; R' is hydrogen or lower alkyl; L2 is a bond, -C(0)NH-, -NH-, -CH2NHC(O)-, -NHC(O)- or -NHC(0)NH-; R is hydrogen, halogen, lower alkoxy, cyano or is phenyl optionally substituted by one or more substituents, selected from halogen, lower alkyl substituted by halogen or lower alkoxy, or is a five or six membered heteroaryl, selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or pyrazolyl, which heteroaryls are optionally substituted by one or more substituents, selected from halogen, lower alkyl, lower alkoxy, cyano, cycloalkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or by phenyl substituted by halogen; N is a ring nitrogen atom in position 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region

Ritonavir (RTV), an HIV-1 protease inhibitor (PI), is also a potent mechanism-based inhibitor of human cytochrome P450 3A (CYP3A) and has been widely prescribed as a pharmacoenhancer. As a boosting agent for marketed PIs, it reduces pill burden, and improves compliance. Removal of the hydroxyl group from RTV reduces, but does not eliminate HIV PI activity and does not affect CYP3A inhibition. Herein we report the discovery of a novel series of CYP3A inhibitors that are devoid of antiviral activity. The synthesis and evaluation of analogs with extensive modifications of the 1,4-diamine core along with the structure activity relationships with respect to anti-HIV activity, CYP3A inhibitory activity, selectivity against other CYP enzymes and the human pregnane X receptor (PXR) will be discussed.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.